Lavasa

Quick links to important sections

Lavasa

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lavasa

Quick Facts

Feature Detail
Active Ingredient Omega-3-acid ethyl esters
Classification Antilipemic agent
Primary Use Reducing very high blood triglyceride levels (ge 500 mg/dL)

Lavasa (omega-3-acid ethyl esters) is a prescription medicine used in adult patients to help lower very high levels of triglycerides (ge 500 mg/dL) in the blood. It is intended for use as an adjunct, or addition, to an appropriate diet that focuses on reducing fat intake.

Lavasa is a formulation of highly purified omega-3 fatty acids, specifically the ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are derived from fish oils. While the exact mechanism is not fully understood, the proposed actions include decreasing the liver’s production of triglycerides and increasing the breakdown and removal of triglycerides from the body.

Elevated triglycerides (a type of fat in the blood) is a condition called hypertriglyceridemia, which is associated with an increased risk of developing pancreatitis, a serious condition involving inflammation of the pancreas. Lavasa's use is specifically targeted at this severe form of hypertriglyceridemia.

Regulatory References

  1. NIH MedlinePlus: Omega-3-acid ethyl esters

What side effects are possible with Lavasa?

Lavasa (omega-3-acid ethyl esters) is associated with officially documented adverse reactions and specific safety considerations based on governmental regulatory filings.

Most Common Adverse Reactions

The most common adverse reactions reported in clinical trials, occurring in at least 3% of patients and at a greater rate than in patients receiving placebo, are primarily gastrointestinal:

  • Eructation (burping)
  • Dyspepsia (upset stomach)
  • Taste perversion (changes in taste)

Additional adverse reactions observed in clinical trials included constipation, vomiting, pruritus (itching), rash, and increases in liver enzymes (ALT and AST).


Serious Safety Information and Precautions

Contraindication: The medicine is contraindicated in patients with a known history of hypersensitivity (e.g., anaphylactic reaction) to Lavasa or any of its components.

Bleeding Risk: Lavasa is associated with an increased risk of bleeding events. This risk is greater in patients also taking anticoagulant or antiplatelet medications (such as warfarin or aspirin). Patients on such concomitant therapies require monitoring.

Heart Rhythm: There is a documented association with an increased risk of atrial fibrillation or flutter requiring hospitalization, particularly in the initial months of starting therapy. This risk is noted to be greater in patients with a previous history of these heart rhythm problems.

Monitoring: Periodic laboratory monitoring of LDL-C (low-density lipoprotein cholesterol) levels is required during treatment. For patients with hepatic impairment, Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) levels must be monitored periodically.

Allergies: Since the drug is derived from fish oil, it should be used with caution in patients with a known hypersensitivity to fish and/or shellfish, although the exact risk of an allergic reaction is not established.

Overdose and Emergency Response

Overdose and when to seek help

Experience with the overdose of omega-3-acid ethyl esters is limited, as stated in regulatory prescribing information. The clinical presentation in an overdose scenario is anticipated to be an exaggeration of the medicine's known adverse effects. Ingestion of doses above the prescribed level may lead to an increase in the incidence or severity of known adverse reactions, such as gastrointestinal symptoms.

Severe Outcomes and Immediate Action

The overdose profile requires immediate intervention due to the potential for severe outcomes. Due to the drug's properties, overdose may amplify the risk of bleeding, which is a key physiological system affected, particularly in individuals taking concurrent antiplatelet or anticoagulant medications. The potential for severe, immediate hypersensitivity reactions, such as anaphylaxis, is also a consideration.

Immediate medical attention is required for any known or suspected overdose. The official regulatory response mandates that patients contact a doctor or a poison control center immediately, ensuring professional assessment and intervention regardless of the apparent severity.

Management Protocol

Regulatory documents confirm that no specific antidote is known for omega-3-acid ethyl esters. Consequently, the management of overdose is defined as strictly symptomatic and supportive treatment, instituted by healthcare professionals based on the patient's specific clinical signs and manifestations. This non-specific approach is the standard procedure defined in the official labeling.

Therapeutic Uses of Lavasa

What Lavasa Treats: Main Uses and Benefits

Lavasa is applied in clinical settings that involve acute or unstable symptom patterns to offer symptomatic relief and support during acute episodes. It is primarily used when symptoms that interfere with daily functioning become noticeable, assisting patients in managing periods of acute discomfort. Lavasa is generally considered relevant when short-term symptomatic assistance is needed.

Lavasa is commonly used across conditions presenting with acute episodes and situations involving recurrent or fluctuating manifestations, focusing on easing symptoms of increased distress or discomfort. The medication helps address symptom clusters that may become intense or disruptive by managing manifestations related to physical discomfort, heightened physiological activity, and noticeable physiological strain. The use of symptomatic treatment is consistent with therapeutic guidance.

The treatment provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptoms That Interfere With Daily Functioning

Regulatory References

  1. European Medicines Agency (EMA) guide on therapeutic indications

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lavasa?

Lavasa (omega-3-acid ethyl esters) is indicated for use in adult patients whose fasting triglyceride levels are 500 mg/dL or greater, strictly as an adjunct to an appropriate lipid-lowering diet.

Classification Population Status Defined by Regulators
Absolute Contraindication Known hypersensitivity (e.g., anaphylactic reaction) to Lavasa or any of its components. Must Not Use
Target Population Adults (ge 18 years) with severe hypertriglyceridemia. Allowed
Age Restriction Pediatric patients (under 18 years). Safety/Efficacy Not Established

Conditional Use and Restrictions

Certain populations require caution or monitoring as specified in the official labeling:

  • Hepatic Impairment: Liver enzyme levels (ALT and AST) must be monitored periodically during therapy.
  • Cardiac Conditions: Use with caution in patients with a history of atrial fibrillation or flutter.
  • Allergy Risk: Caution is advised for patients with a known hypersensitivity to fish and/or shellfish.
  • Pregnancy and Lactation: Use during pregnancy is conditional, permitted only if the potential benefit outweighs the potential risk. Caution is advised for nursing mothers, as it is unknown if the medicine is excreted in human milk.

The regulatory profile clearly limits the eligible population to adults with the specified severe blood triglyceride level while flagging specific conditions that necessitate special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lavasa (omega-3-acid ethyl esters) is defined by its potential pharmacodynamic effects and specific monitoring requirements, as detailed in government regulatory documents.

Interaction Category Officially Documented Pattern and Constraint
Pharmacodynamic Interaction Co-administration with anticoagulants or other drugs affecting coagulation (such as anti-platelet agents) may result in a prolongation of bleeding time. This documented interaction requires the patient's coagulation status to be monitored periodically throughout the course of therapy.
Exposure-Modifying Effect Lavasa may lead to increases in Low-Density Lipoprotein Cholesterol (LDL-C) and non-HDL-C levels in some individuals. Due to this official regulatory finding, the periodic monitoring of these lipid parameters is required while receiving treatment.
Metabolic Pathway Status Clinically significant Cytochrome P450-mediated drug-drug interactions are not expected in humans. This classification is based on the rapid clearance and metabolism of the active components, EPA and DHA, in the circulation.

Official Interaction Statements and Restrictions

  • No specific drug-drug combinations are formally classified as contraindicated due to interaction risk in the regulatory labels reviewed.
  • The medication requires periodic monitoring of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) levels in patients with documented hepatic impairment, which is a population-specific caution related to interaction management.
  • No mandatory timing separation rules are documented for co-administered substances.

The structure of the interaction profile centers on mandatory monitoring and pharmacodynamic effects rather than metabolic inhibition or induction. This information is derived exclusively from authoritative government sources.

Mechanism of Action

Lavasa (omega-3-acid ethyl esters, containing EPA and DHA) modulates lipid metabolism through a dual action that restricts fat production and accelerates fat breakdown. Its mechanism includes nuclear receptor modulation and enzyme inhibition.

Modulating Hepatic Fat Production

This mechanism acts within the liver's capacity to synthesize triglycerides. The active ingredients function as agonists for PPARalpha and inhibit enzymes like DGAT, while also suppressing the transcriptional regulator SREBP-1c. This process decreases the formation and secretion of triglyceride-rich VLDL from the liver, modulating the production component of plasma lipid transport.

Enhancing Systemic Triglyceride Clearance

This domain accelerates the removal of circulating triglycerides from the plasma. The mechanism involves the up-regulation and activation of Lipoprotein Lipase ( LPL), an enzyme that rapidly hydrolyzes triglycerides within circulating VLDL and chylomicrons. This effect facilitates the swift breakdown and clearance of fat particles in the bloodstream, contributing to the net decrease in plasma triglyceride concentrations. The EPA and DHA components exhibit complementary actions, targeting both fat production and clearance pathways simultaneously.

Dosage and Administration Information

How to Use Lavasa

Lavasa (omega-3-acid ethyl esters) is used according to a precise protocol established for adults with severe hypertriglyceridemia (triglyceride levels ge 500 mg/dL). The medication is strictly administered orally in capsule form.


Official Administration Guidelines

Instruction Detail
Route of administration: Oral
Standard Dosing Regimen: The mandatory total daily dose is 4 grams (four 1-gram capsules) for the approved indication.
Frequency and Schedule: The 4-gram daily dose may be taken as a single dose once a day or divided into two doses of 2 grams each (twice daily).
Timing in relation to meals: Must be administered with meals.
Preparation Requirements: Capsules must be swallowed whole; patients should not break open, crush, dissolve, or chew them.
Course Duration: The efficacy of the treatment should be periodically assessed. Therapy is withdrawn if an adequate response is not achieved after two months of treatment.

Use-Context and Population Rules

Lavasa therapy is intended to be used only as an adjunct to an appropriate lipid-lowering diet that is initiated prior to starting the medication. The adherence to this diet must be maintained throughout the treatment period.

The labeling specifies that safety and effectiveness in pediatric patients (under 18 years of age) have not been established. For patients with existing liver impairment, guidelines require that liver enzyme levels (ALT and AST) be monitored periodically during the course of therapy. This standardized procedural structure defines the high-level use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lavasa

Evidence for Use in Severe Hypertriglyceridemia

The primary clinical evaluation for Lavasa (omega-3-acid ethyl esters) has focused on adult patients who have very high fasting triglyceride levels, typically measuring 500 mg/dL or higher. Researchers examined this use through several short-term, randomized, double-blind, placebo-controlled trials. These studies monitored the patients’ blood lipid levels while they were following a prescribed diet, collecting measurements over periods generally lasting a few months. The main focus was on measuring changes in specific blood lipid markers during the study period.

Findings describe patterns observed in the studies related to the central measurement: the change in fasting serum triglyceride levels. Trials reported measurements related to the primary biomarker in the observed study group compared to the placebo group. It is important to note that these observations were recorded over relatively short follow-up durations.

Research on Long-Term Clinical Outcomes

Research has also explored the potential for this drug class to influence major clinical endpoints, such as heart attack and stroke. This investigation was conducted using large-scale, long-term Cardiovascular Outcomes Trials (CVOTs), structured to monitor the occurrence of major adverse cardiovascular events (MACE) over several years in high-risk adult populations.

The results from trials using the specific EPA/DHA combined formulation have been mixed regarding the evaluation of these major cardiovascular events. While research involving a related, distinct formulation (EPA-only) described specific findings regarding MACE, similar consistent reports were not made for the combined EPA/DHA product used in Lavasa across all studies. The scientific literature describes that study results vary based on the specific composition of the omega-3 formulations when evaluating long-term clinical outcomes.

Areas of Ongoing Research and Uncertainty

Scientific research highlights several areas where certainty remains low or where long-term effects are not fully established. A major limitation noted in the pivotal trials is that the research has not determined the medication's effect on the incidence of pancreatitis, the serious clinical condition associated with very high triglycerides. The studies monitored biomarkers, but they were not specifically powered to determine the impact on this key clinical outcome.

Data for certain groups remain insufficient. For instance, there is limited information available from randomized trials on the effects of Lavasa in pediatric or pregnant patients. Research is ongoing to explore the relationship between the combined EPA/DHA formulation and cardiovascular event outcomes.

Key Studies & References

  1. OMEGA-3-ACID ETHYL ESTERS (Lovaza) - FDA Approved Labeling Text
  2. Omega-3-acid ethyl ester medicines: dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases - EMA/PRAC Safety Communication
  3. Impact of Omega-3 Fatty Acids on Cardiovascular Disease Prevention (Meta-analysis reporting mixed results across different formulations)

Frequently Asked Questions (FAQ)

Common questions about Lavasa (FAQ)


Q: How quickly does Lavasa start working after I take it?

Studies and official information indicate that the therapeutic effect is assessed over time. Official regulatory guidelines state that the course of therapy should be withdrawn if an adequate reduction in triglyceride levels is not achieved after two months of treatment.


Q: Is Lavasa safe to take with common pain relievers like ibuprofen?

Regulatory documents indicate that taking Lavasa alongside other medications that affect blood clotting, such as antiplatelet agents, may prolong bleeding time. Therefore, the official interaction profile requires that the patient's coagulation status be monitored periodically throughout the course of therapy.


Q: Is Lavasa commonly used in older adults?

Clinical studies included patients older than 65 years in their evaluations. According to official documents, the findings on safety and effectiveness in subjects over 60 years old did not appear to differ from those observed in younger adult subjects.


Q: What are the long-term safety concerns associated with taking Lavasa?

Research has investigated the medication's effects over extended periods. The official labeling notes that the drug's effect on cardiovascular mortality and morbidity (such as heart attack or stroke) has not been determined.


Q: What should I do if I notice an allergic reaction to Lavasa?

Lavasa is contraindicated for patients with a known hypersensitivity to the drug or its components. The regulatory text advises that stopping the medicine and seeking emergency medical help right away is the procedural step if symptoms of a serious allergic reaction occur.


Q: Are there restrictions on specific foods or juices while on Lavasa?

The medication is strictly indicated for use as an adjunct to an appropriate lipid-lowering diet. Official regulatory documents indicate that factors like excess alcohol intake are important to address during therapy, as they may contribute to high triglyceride levels.


Q: Why do doctors check bloodwork before prescribing Lavasa?

Laboratory studies must be performed to confirm that the patient's blood lipid levels are consistently and severely abnormal. This initial check is necessary to confirm the diagnosis and ensure the medication is appropriate for the approved indication.


Q: Is there a maximum time someone is advised to take Lavasa?

The duration of treatment is determined by how well the medication is working. Official guidance states that therapy should be withdrawn in patients who do not achieve an adequate reduction in triglyceride levels after two months of treatment.


Q: What are the risks of taking Lavasa with other heart medications?

Regulatory studies examined the co-administration of Lavasa with other common cardiovascular drugs, specifically statins (HMG-CoA reductase inhibitors). Findings indicated that Lavasa showed no measurable effect on the concentration or exposure of these statins in the body.


Q: Is Lavasa a preventative medicine?

Lavasa is officially indicated as an adjunct to diet to reduce very high triglyceride levels in adults. While research has explored the drug class's potential to influence long-term cardiovascular events, the official labeling states that the drug's effect on cardiovascular mortality and morbidity has not been determined.


Q: Is Lavasa considered a blood pressure medicine?

No, Lavasa is officially classified as an antilipemic agent. The drug is indicated as an adjunct to diet to reduce very high triglyceride levels (ge 500 mg/dL), and is not indicated for the treatment of high blood pressure (hypertension).


Q: What happens if I miss a dose of Lavasa?

If a dose is missed, regulatory patient information advises taking it as soon as it is remembered. However, the official information notes that if an entire day is missed, the recommended procedure is not to double the dose the next time it is taken.


Q: Is Lavasa known to cause weight gain?

Weight gain is not listed among the most common adverse reactions reported in clinical trials. However, regulatory documents note that the medication may be less effective if the patient is overweight or obese, a factor that requires the patient to maintain a lipid-lowering diet.


Q: Can Lavasa make you feel tired or dizzy?

Common side effects are primarily gastrointestinal in nature, such as burping or upset stomach. Official adverse reaction data does list dizziness as a possible side effect, though the incidence (how often it occurs) is not known (it is not reported as common).


Q: What is the list of ingredients in Lavasa besides the main active component?

The active ingredient is omega-3-acid ethyl esters. The capsule contains inactive ingredients such as alpha-tocopherol (an antioxidant), as well as components that form the capsule shell, including gelatin, glycerol, and purified water.


Q: Does Lavasa interact with any herbal supplements?

Official patient guidance states that it is important to discuss all co-administered substances with a doctor before taking the medicine. This instruction includes other over-the-counter products, as well as herbal or vitamin supplements.


Q: Is it safe to drink alcohol while taking Lavasa?

Official documents highlight that excessive alcohol intake is recognized as an important factor that contributes to high triglyceride levels. Alcohol consumption should therefore be addressed before and throughout the course of drug therapy.


Q: What is the risk of stopping Lavasa suddenly?

The condition Lavasa treats requires continuous management to remain under control. The regulatory guidance is that stopping or changing the dose must not occur without appropriate medical oversight.


Q: Is there any difference between the brand name Lavasa and the generic version?

The Food and Drug Administration ( FDA) requires that generic versions of omega-3-acid ethyl esters meet specific quality and quantitative ranges for the active components ( EPA and DHA). The regulatory process aims to ensure that the generic product is equivalent in performance and dose to the brand-name product.


Q: Is Lavasa a habit-forming or addictive drug?

The official FDA prescribing information includes a dedicated section to address Drug Abuse and Dependence. This regulatory inclusion ensures that any potential for abuse or dependence is officially reported and documented.


Q: Is it possible for Lavasa to stop working over time?

The official guidance emphasizes that the effectiveness of the drug must be regularly monitored. It mandates that patients undergo periodic laboratory studies to check triglyceride levels, and that therapy be discontinued if the desired response is not achieved.


Q: Is Lavasa available over the counter in any country?

In the United States, the product is indicated to treat a severe medical condition (ge 500 mg/dL triglycerides) and is manufactured and distributed as a prescription-only medication.


Q: Why is Lavasa a prescription-only medication?

The medication is indicated to treat a severe medical condition (very high triglycerides), requires periodic blood monitoring, and is associated with specific safety warnings that necessitate medical oversight.


Q: Is it safe to drive after taking Lavasa?

Official adverse reaction data lists dizziness as a possible side effect, though the incidence is not known. Because dizziness is a potential side effect, patients are advised to consider how the medication affects them before driving or operating heavy machinery.


Q: Can Lavasa impact fertility?

The official FDA prescribing information includes a dedicated nonclinical toxicology section that addresses Carcinogenesis, Mutagenesis, and Impairment of Fertility. This section summarizes the findings regarding potential effects on reproduction.


Q: What happens if I take too much Lavasa?

Official patient information advises that if too much of the medicine is taken or an overdose occurs, the procedural step is to call a doctor or Poison Control Center right away for immediate guidance.

How should Lavasa be stored and disposed of?

Storage and Disposal Requirements

LOVAZA (omega-3-acid ethyl esters) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted from 15 C to 30 C (59 F to 86 F). The product must not be frozen to preserve the integrity of the soft gelatin capsules. To ensure stability, the medication should be kept away from excessive heat, moisture, and direct light, and stored in a closed container (original packaging).

Consistent with official labeling for all prescription medicines, LOVAZA must be kept out of the reach of children.

Disposal of unused or expired LOVAZA should follow official federal and local guidelines, such as using a drug take-back program. If no take-back program is available, the product should be mixed with an undesirable substance, sealed in a container, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lavasa found in:

A-Z Index: